Patients with CD36 Deficiency Are Associated with Enhanced Atherosclerotic Cardiovascular Diseases

Access this Article

Author(s)

    • Yuasa-Kawase Miyako
    • Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.
    • Matsuyama Akifumi
    • Department of Somatic Stem Cell Therapy, Institute of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation.
    • Nishida Makoto
    • Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.|Health Care Center, Osaka University.
    • Ishigami Masato
    • Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine.
    • Komuro Issei
    • Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.
    • Yamashita Shizuya
    • Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.
    • Masuda Daisaku
    • Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.
    • Yamashita Taiji
    • Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.
    • Kawase Ryota
    • Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.
    • Nakaoka Hajime
    • Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.
    • Inagaki Miwako
    • Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.
    • Nakatani Kazuhiro
    • Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.
    • Ohama Tohru
    • Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine.|Health Care Center, Osaka University.

Abstract

Aim: The clustering of dyslipidemia, impaired glucose tolerance and hypertension increases the morbidity and mortality from cardiovascular events. A class B scavenger receptor, CD36, is a receptor for oxidized LDL and a transporter of long-chain fatty acids. Because of the impaired uptake of oxidized LDL in CD36-deficient macrophages and from the results of CD36 knockout mice, CD36 deficiency (CD36-D) was supposed to be associated with reduced risks for coronary artery disease (CAD); however, CD36-D patients are often accompanied by a clustering of coronary risk factors. The current study aimed to investigate the morbidity and severity of cardiovascular diseases in CD36-D patients.<BR>Methods: By screening for CD36 antigen on platelets and monocytes using FACS or the absent myocardial accumulation of <sup>123</sup>I-BMIPP by scintigraphy, 40 patients with type I CD36-D were collected, the morbidity of CAD and their features of atherosclerotic cardiovascular diseases were observed. Screening for CD36-D in both CAD patients (<i>n</i> =319) and healthy subjects (<i>n</i> =1,239) were underwent.<BR>Results: The morbidity of CAD was significantly higher in CD36-D patients than in the general population; 50% of patients (20 out of 40) had CAD identified by BMIPP scintigraphy and 37.5% (3 out of 8) by FACS screening, respectively. Three representative CD36-D cases demonstrated severe CAD and atherosclerosis. The frequency of CD36-D was three times higher in CAD patients than in healthy subjects (0.9% vs 0.3%, <i>p</i> <0.0001).<BR>Conclusion: The morbidity of CAD is significantly higher in CD36-D patients suffering from severe atherosclerosis, implying that the status of CD36-D might be atherogenic.

Journal

  • Journal of Atherosclerosis and Thrombosis

    Journal of Atherosclerosis and Thrombosis 19(3), 263-275, 2012

    Japan Atherosclerosis Society

Codes

  • NII Article ID (NAID)
    130004444587
  • Text Lang
    ENG
  • ISSN
    1340-3478
  • Data Source
    J-STAGE 
Page Top